Emerging infectious diseases · 2017 · 380 citations · 23 references
MedicineInfectious DiseasesPreventive MedicineDisease PreventionDisease SurveillanceImmunizationImmunization PolicyVaccinationVaccination PolicyVaccine PolicyVaccine-preventable DiseasesViral HepatitisChronic Viral HepatitisHepatitis B Vaccination PolicyHepatitis B Virus ProphylaxisHepatitis Virus VaccinationSample Size CalculationVaccination Policy EvaluationVaccine-preventable Disease SurveillanceViral Hepatitis Prevention
China's hepatitis B virus (HBV) prevention policy has been evaluated through nationally representative serologic surveys conducted in 1992 and 2006. We report results of a 2014 serologic survey and reanalysis of the 1992 and 2006 surveys in the context of program policy. The 2014 survey used a 2-stage sample strategy in which townships were selected from 160 longstanding, nationally representative, county-level disease surveillance points, and persons 1-29 years of age were invited to participate. The 2014 sample size was 31,713; the response rate was 83.3%. Compared with the 1992 pre-recombinant vaccine survey, HBV surface antigen prevalence declined 46% by 2006 and by 52% by 2014. Among children <5 years of age, the decline was 97%. China's HBV prevention program, targeted toward interrupting perinatal transmission, has been highly successful and increasingly effective. However, this progress must be sustained for decades to come, and elimination of HBV transmission will require augmented strategies.
23
Tackling the challenges to health equity in China
Shenglan Tang, Qingyue Meng, Lincoln Chen et al. · The Lancet · 2008 · 523 citations · Full text
Chein‐Shan Liu, Hong Cao, Shengli Bi et al. · International Hepatology Communications · 1996 · 240 citations